Search

Displaying results 3101 - 3110 of 7706 in total
  1. Drug

    Idarubicin

    go.drugbank.com/drugs/DB01177
    ApprovedInvestigational

    An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

    Products: IDARALEM RU, IDARUBICINA MYLAN GENERICS
  2. Drug

    Etomidate

    go.drugbank.com/drugs/DB00292
    ApprovedInvestigational

    It has been proposed as an induction anesthetic.

  3. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

  4. Drug

    Votucalis

    go.drugbank.com/drugs/DB05032
    Investigational

    It is a topically delivered small protein that acts as an anti-inflammatory agent.

  5. Drug

    LIC-477

    go.drugbank.com/drugs/DB05363
    Experimental

    LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.

  6. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  7. Drug

    Gadobutrol

    go.drugbank.com/drugs/DB06703
    ApprovedInvestigational

    Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume. … [A7001] Like other GBCA, gadobutrol usage carries the risk of nephrogenic systemic fibrosis (NSF) due to the dissociation of gadolinium from the chelates, although gadobutrol tends to have a lower risk

  8. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug. … The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C.

  9. Drug

    Azaperone

    go.drugbank.com/drugs/DB11376
    InvestigationalVet approved

    More rarely it may be used in humans as an antipsychotic drug, but this is uncommon.

    Categories: Dopamine D2 Receptor Antagonists
  10. Drug

    Glyceryl monostearate

    go.drugbank.com/drugs/DB11250
    Approved

    It is commonly used as an emulsifier in foods.